Shah Parveen, Robbani Irfan, Shah Omar
Department of Pathology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kasmir, 190010, India.
Ann Saudi Med. 2009 Jul-Aug;29(4):288-93. doi: 10.4103/0256-4947.55314.
Because breast cancer in men is rare, few patients are available for prospective studies. To learn more about its epidemiology, risk factors, clinical features, genetics and pathology in our country, we conducted a retrospective study of all cases seen in recent decades at our institution.
We identified each case of male breast cancer in the database at the Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India, between the years 1983 to 2007.
We identified only 32 cases of male breast cancer over the 24-year period. Male breast cancer accounted for 32 (2.8%) of 1141 resected breast specimens, which included all breast lesions and 32 (4.1%) of 780 breast cancer cases. Of the 32 cases, 20 (62.5%) had various associated risk factors. Invasive ductal carcinoma was seen in 30 cases (93.7%). Of 20 cases that underwent molecular studies, 16 (80%) patients had estrogen receptor positivity whereas 14 (70%) had progesterone receptor positivity. Six cases (30%) overexpressed HER2 and p53. The BRCA2 mutation was observed in 4 cases (40%) while no patient presented with the BRCA1 mutation.
An incidence of 4.1% for male breast cancer indicates that this disease is not as uncommon as presumed in this part of the world. Breast cancer in men seems more frequently to be hormone receptor positive and the BRCA2 mutation confers a significant risk to men.
由于男性乳腺癌较为罕见,可供前瞻性研究的患者数量很少。为了更深入了解我国男性乳腺癌的流行病学、危险因素、临床特征、遗传学及病理学情况,我们对近几十年来在本机构就诊的所有病例进行了一项回顾性研究。
我们在印度克什米尔地区斯利那加市的谢里·克什米尔医学科学研究所的数据库中,识别出1983年至2007年间的每一例男性乳腺癌病例。
在这24年期间,我们仅识别出32例男性乳腺癌病例。男性乳腺癌占1141例切除乳腺标本的32例(2.8%),其中包括所有乳腺病变,占780例乳腺癌病例的32例(4.1%)。在这32例病例中,20例(62.5%)存在各种相关危险因素。30例(93.7%)为浸润性导管癌。在接受分子研究的20例病例中,16例(80%)患者雌激素受体呈阳性,而14例(70%)孕激素受体呈阳性。6例(30%)HER2和p53过表达。4例(40%)观察到BRCA2突变,而没有患者出现BRCA1突变。
男性乳腺癌发病率为4.1%,表明该病在世界这一地区并不像人们认为的那样罕见。男性乳腺癌似乎更常为激素受体阳性,BRCA2突变给男性带来显著风险。